Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition
Open Access
- 9 May 2026
- journal article
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (2) , 201229
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Austrian Science Fund
- Bundesministerium Bildung
- Universiteit Gent
- Österreichische Forschungsförderungsgesellschaft (7940628)
This publication has 85 references indexed in Scilit:
- Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolutionCell, 2025
- High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcomaCancer Letters, 2022
- Why 90% of clinical drug development fails and how to improve it?Acta Pharmaceutica Sinica B, 2022
- Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at Single-Cell ResolutionCell Reports, 2020
- Thiol–Gelatin–Norbornene Bioink for Laser‐Based High‐Definition BioprintingAdvanced Healthcare Materials, 2019
- Highly Reactive Thiol‐Norbornene Photo‐Click Hydrogels: Toward Improved ProcessabilityMacromolecular Rapid Communications, 2018
- Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effortGenes, Chromosomes and Cancer, 2009
- Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell typesBiotechnology and Bioengineering, 2003
- Chromosomal regions involved in the pathogenesis of osteosarcomasGenes, Chromosomes and Cancer, 2000
- EWS‐FLI‐1 and EWS‐ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumorInternational Journal of Cancer, 1995